| 000 | 01790 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515125413.0 | ||
| 264 | 0 | _c20080908 | |
| 008 | 200809s 0 0 eng d | ||
| 022 | _a1535-7163 | ||
| 024 | 7 |
_a10.1158/1535-7163.MCT-08-0046 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiller, Robert E | |
| 245 | 0 | 0 |
_aRANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. _h[electronic resource] |
| 260 |
_bMolecular cancer therapeutics _cJul 2008 |
||
| 300 |
_a2160-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aBone Neoplasms _xcomplications |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Nude |
| 650 | 0 | 4 |
_aOsteolysis _xcomplications |
| 650 | 0 | 4 |
_aOsteoprotegerin _xpharmacology |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xpathology |
| 650 | 0 | 4 |
_aRANK Ligand _xantagonists & inhibitors |
| 650 | 0 | 4 | _aReceptors, Fc |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTaxoids _xpharmacology |
| 650 | 0 | 4 |
_aTumor Burden _xdrug effects |
| 650 | 0 | 4 | _aWhole Body Imaging |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aRoudier, Martine | |
| 700 | 1 | _aJones, Jon | |
| 700 | 1 | _aArmstrong, Allison | |
| 700 | 1 | _aCanon, Jude | |
| 700 | 1 | _aDougall, William C | |
| 773 | 0 |
_tMolecular cancer therapeutics _gvol. 7 _gno. 7 _gp. 2160-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1535-7163.MCT-08-0046 _zAvailable from publisher's website |
| 999 |
_c18088936 _d18088936 |
||